Sophiris Bio Inc. (NASDAQ:SPHS) dropped 6.9% during trading on Tuesday . The stock traded as low as $4.88 and last traded at $5.11, with a volume of 2,203,446 shares changing hands. The stock had previously closed at $5.49.

SPHS has been the topic of several recent research reports. Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th. Echelon Wealth Partners reaffirmed a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th.

The company’s 50 day moving average is $3.17 and its 200-day moving average is $1.94. The firm’s market cap is $110.74 million.

Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06. On average, analysts anticipate that Sophiris Bio Inc. will post ($0.73) EPS for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.